CLINICAL TRIALS PROFILE FOR ORTHO TRI-CYCLEN LO

All Clinical Trials for Ortho Tri-cyclen Lo

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00320567 ↗	The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa	Completed	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Phase 2	1969-12-31	The purpose of this study is to evaluate the effect of norgestimate/ethinyl estradiol on lumbar spine (L1-L4) and total hip bone mineral density (BMD) in pediatric subjects with anorexia nervosa.
NCT00344383 ↗	An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen	Completed	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Phase 2	2003-11-01	The purpose of this study is to evaluate the bleeding profile of norgestimate/ethinyl estradiol, an oral contraceptive tablet, given in an extended regimen
NCT00439972 ↗	Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity	Unknown status	Ortho-McNeil Pharmaceutical	Phase 2	2007-02-01	The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status.
NCT00439972 ↗	Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity	Unknown status	University of Washington	Phase 2	2007-02-01	The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status.

Clinical Trial Conditions for Ortho Tri-cyclen Lo

Condition Name

Condition Name for Ortho Tri-cyclen Lo
Intervention	Trials
Healthy	5
Contraception	4
Pharmacokinetics	4
Drug Interactions	2

Condition MeSH

Condition MeSH for Ortho Tri-cyclen Lo
Intervention	Trials
Hepatitis C	3
Hepatitis C, Chronic	1
Diabetes Mellitus, Type 2	1
Diabetes Mellitus	1

Clinical Trial Locations for Ortho Tri-cyclen Lo

Trials by Country

Trials by Country for Ortho Tri-cyclen Lo
Location	Trials
United States	34
Canada	10
New Zealand	1
Netherlands	1

Trials by US State

Trials by US State for Ortho Tri-cyclen Lo
Location	Trials
Texas	6
Florida	3
Kansas	2
Wisconsin	2
Indiana	2

Clinical Trial Progress for Ortho Tri-cyclen Lo

Clinical Trial Phase

Clinical Trial Phase for Ortho Tri-cyclen Lo
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	3

Clinical Trial Status

Clinical Trial Status for Ortho Tri-cyclen Lo
Clinical Trial Phase	Trials
Completed	17
Unknown status	2
Suspended	1

Clinical Trial Sponsors for Ortho Tri-cyclen Lo

Sponsor Name

Sponsor Name for Ortho Tri-cyclen Lo
Sponsor	Trials
Eli Lilly and Company	3
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2
Bristol-Myers Squibb	2

Sponsor Type

Sponsor Type for Ortho Tri-cyclen Lo
Sponsor	Trials
Industry	22
Other	1